

- **Name:** Dae-Won Lee
 - **Current Position & Affiliation:** Assistant professor, Seoul National University
College of Medicine, Seoul
 - **Country:** Korea
-

• Educational Background:

PhD 2018 - 2025 Translational Medicine, Department of Medicine, Graduate School, Seoul National University, Seoul, Korea
M.Sc 2012 - 2014 Molecular and Clinical Oncology, Department of Medicine, Seoul National University, Seoul, Korea
M.D. 2003 - 2009 Ulsan University College of Medicine, Seoul, Korea

• Professional Experience:

2021- Assistant professor, Seoul National University College of Medicine, Seoul, Korea
2018-2021 Clinical Assistant professor, Department of Internal Medicine, SNUH, Seoul, Korea
2017-2018 Clinical fellow, Division of Hematology and Medical Oncology, Department of Internal Medicine, SNUH, Seoul, Korea
2010-2014 Resident, Department of Internal Medicine, SNUH, Seoul, Korea
2009-2010 Intern, SNUH, Seoul, Korea

• Professional Organizations:

The Korean Association of Internal Medicine	2010
Korean Cancer Study Group	2013
Korean Society of Medical Oncology	2013
American Society of Clinical Oncology (ASCO)	2013
American Association for Cancer Research (AACR)	2015
European Society for Medical Oncology (ESMO)	2023

• Main Scientific Publications:

1. Lee DW, Ryu HS, Nikas IP, Koh J, Kim TY, Kim HK, Lee HB, Moon HG, Han W, Lee KH, Im SA. Immune marker expression and prognosis of early breast cancer expressing HER3. Eur J Cancer. 2024 Dec;213:115081
2. Lee DW, Jung KH, Lee KH, Park YH, Lee KS, Sohn J, Ahn HK, Jeong JH, Koh SJ, Kim JH, Kim HJ, Lee KE, Kim HJ, Yang YW, Park KH, Lee J, Won HS, Kim TY, Im SA. Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial. Eur J Cancer. 2024 Jan;197:113456
3. Seo J, Koh J, Lee DW (Corresponding author), Kim J, Ryu HS, Lee KH, Kim TY, Im SA. HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results. Breast Cancer Res. 2023 Dec 14;25(1):154.
4. Lee DW, Lim Y, Kim HP, Kim SY, Roh H, Kang JK, Lee KH, Kim MJ, Ryoo SB, Park JW, Jeong SY, Park KJ, Kang GH, Han SW, Kim TY. Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer. Cancer Res Treat. 2023 Jul;55(3):927-938.
5. Lee DW, Keam B, Lee KS, Ahn JH, Sohn J, Ahn JS, Lee MH, Kim JH, Lee KE, Kim HJ, Kim SY,

Park YH, Ock CY, Lee KH, Han SW, Kim SB, Im YH, Chung HC, Oh DY, Im SA. A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03). *Cancer Res Treat.* 2023 Apr;55(2):523-530.

6. Park SY, Suh KJ, Lee DW (Corresponding author), Ryu HS, Kim M, Kim SH, Lee KH, Kim TY, Kim JH, Park IA, Im SA. Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy. *Breast Cancer Res Treat.* 2022 Nov;196(1):121-128.

7. Kim JS, Suh KJ, Lee DW (Corresponding author), Woo GU, Kim M, Kim SH, Ryu HS, Lee KH, Kim TY, Han SW, Park SY, Park IA, Kim JH, Im SA. A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer. *Cancer Res Treat.* 2022 Apr;54(2):488-496.

8. Lee DW, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Kim TY, Han SW, Oh DY, Im SA, Kim TY, Lee Y, Kim H, Lee KH. Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. *Clin Cancer Res.* 2021 Feb 1;27(3):713-718.

9. Lee DW, Ryu HS, Jin MS, Lee KH, Suh KJ, Youk J, Kim JY, Min A, Lee HB, Moon HG, Kim TY, Han SW, Oh DY, Han W, Park IA, Noh DY, Im SA. Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients. *Br J Cancer.* 2019 Jul;121(3):230-236.

10. Lee DW, Han SW, Bae JM, Jang H, Han H, Kim H, Bang D, Jeong SY, Park KJ, Kang GH, Kim TY. Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin. *Clin Cancer Res.* 2019 Oct 15;25(20):6141-6147.